A Zika virus researcher transfers samples at the National Institute of Allergy and Infectious Diseases Vaccine Research Center laboratory. Results from two early-stage clinical trials show an experimental vaccine developed by NIAID scientists is safe and induces an immune response in healthy adults. The results were reported Monday in the medical journal, The Lancet.
A Zika virus researcher transfers samples at the National Institute of Allergy and Infectious Diseases Vaccine Research Center laboratory. Results from two early-stage clinical trials show an experimental vaccine developed by NIAID scientists is safe and induces an immune response in healthy adults. The results were reported Monday in the medical journal, The Lancet. National Institute of Allergy and Infectious Diseases
A Zika virus researcher transfers samples at the National Institute of Allergy and Infectious Diseases Vaccine Research Center laboratory. Results from two early-stage clinical trials show an experimental vaccine developed by NIAID scientists is safe and induces an immune response in healthy adults. The results were reported Monday in the medical journal, The Lancet. National Institute of Allergy and Infectious Diseases